Redeye sees a new investment case in InDex Pharmaceuticals following the discontinuation of CONCLUDE. The share trades at a substantial discount compared to its book value, which offers an interesting play on the company’s future trajectory.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

InDex Pharmaceuticals Q3 2023 - Uncertain future post discontinuation of CONCLUDE

© Modular Finance, source Nordic Press Releases